EBV mRNA vaccine study for healthy young adults
Part of Infections clinical trials.
This study tests a new vaccine designed to protect against Epstein-Barr virus (EBV), a common virus that can cause serious illness. You would receive the vaccine and be monitored to see how safe it is and how your immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 25 years old
- Be in generally good health with no serious medical or mental health conditions
- Never have received an experimental EBV vaccine before
- Not have received any other vaccine in the 56 days before starting the study
- Not be taking strong immune-suppressing medications, or stop them at least 2 weeks before the study
- If you can get pregnant, not be pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
This trial tests a new mRNA-based treatment for people with Epstein-Barr virus (EBV) related diseases, such as certain cancers or EBV illness after a transplant. The goal is to see if the treatment can help your immune system fight the virus and the disease.
This trial tests an mRNA vaccine to treat advanced cancers linked to the Epstein-Barr virus, such as nasopharyngeal cancer, NK/T-cell lymphoma, and stomach cancer. The vaccine teaches your immune system to fight the virus and the cancer.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.